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Abstract
We systematically reviewed data about the effect of exogenous estrogens and progestogens on the course of
migraine during reproductive age. Thereafter a consensus procedure among international experts was undertaken
to develop statements to support clinical decision making, in terms of possible effects on migraine course of
exogenous estrogens and progestogens and on possible treatment of headache associated with the use or with
the withdrawal of hormones. Overall, quality of current evidence is low. Recommendations are provided for all the
compounds with available evidence including the conventional 21/7 combined hormonal contraception, the
desogestrel only oral pill, combined oral contraceptives with shortened pill-free interval, combined oral
contraceptives with estradiol supplementation during the pill-free interval, extended regimen of combined
hormonal contraceptive with pill or patch, combined hormonal contraceptive vaginal ring, transdermal estradiol
supplementation with gel, transdermal estradiol supplementation with patch, subcutaneous estrogen implant with
cyclical oral progestogen. As the quality of available data is poor, further research is needed on this topic to
improve the knowledge about the use of estrogens and progestogens in women with migraine. There is a need for
better management of headaches related to the use of hormones or their withdrawal.
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Introduction
The role of female hormones in the pathogenesis of mi-
graine is well-recognized [1, 2]. Migraine is more preva-
lent in women than in men, it usually starts after
puberty and in many women improves during pregnancy
and after the menopause [1, 3, 4]. The menstrual phase
of the female cycle represents a trigger for migraine at-
tacks in many women [1, 4]. Additionally, exogenous
hormones may change the course of migraine by indu-
cing de novo migraine, inducing de novo aura, worsen-
ing previous migraine but also improving migraine
particularly those attacks related to menstruation [5, 6].
The criteria to diagnose migraine related to menstru-
ation (Table 1) and to diagnose headache related to the
use and to the withdrawal of hormones (Table 2) have var-
ied over years [7–10]. The first version of the International
Classification of Headache Disorders (ICHD), 1988, did
not report any formal criteria for migraine related to men-
struation [7]. The authors recognized that in some women,
migraine without aura (MO) may be almost exclusively
linked with menstruation, so called menstrual migraine
(MM), and indicated that it seemed reasonable to require
that 90% attacks should occur between two days before
menses and the last day of menses. Appendix criteria for
migraine related to menstruation were introduced in 2004,
with the second edition of the ICHD (Table 1) [8]. Two
entities were recognised: pure menstrual migraine (PMM)
where attacks are exclusively related to menstruation;
menstrually related migraine (MRM) where attacks occur
additionally at other times of the cycle. Both were forms of
MO, along with non-menstrual MO or migraine with aura
(MA) in the case of MRM. PMM with aura and MRM
with aura are new entries in the Appendix of the classifica-
tion system available since 2018 [10].
Since the first ICHD classification [7], it was recognized
that headache may be attributable to the use of substances
or their withdrawal but formal categories referring to es-
trogens were introduced in the second edition of the
ICHD (Table 2) [8]. Headache attributable to hormones,
both in the second and the third edition (beta) of the
ICHD, could be diagnosed in the presence of either new
onset headache or of worsening of pre-existing headache
[8, 9]. Criteria also required resolution or return to the
previous pattern after cessation of the hormones. A signifi-
cant change was introduced in 2018 where the diagnosis
of headache attributable to exogenous hormones requires
the presence of headache for at least 15 days per month
[10]. At variance, the diagnosis of estrogen-withdrawal
headache remained substantially unchanged over years
and requires the onset of headache, in women who have
been taking estrogens for three weeks or longer, within
5 days from estrogen withdrawal. However, evidence for
the duration of treatment with estrogen before withdrawal
headache occurs is lacking.
Table 1 Diagnostic criteria of migraine related to menstruation
according to the different editions of the International
Classification of Headache Disorders (ICHD)
ICHD, II edition, 2004
A.1.1.1 Pure menstrual migraine without aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.1
Migraine without aura
B. Attacks occur exclusively on day 1 ± 2 (i.e. days − 2 to + 3) of
menstruation in at least two out of three menstrual cycles and
at no other times of the cycle
A.1.1.2 Menstrually-related migraine without aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.1
Migraine without aura
B. Attacks occur on day 1 ± 2 (i.e. days −2 to + 3) of menstruation
in at least two out of three menstrual cycles and additionally at
other times of the cycle
ICHD, III edition, beta version, 2013
A1.1.1 Pure menstrual migraine without aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.1
Migraine without aura and criterion B below
B. Documented and prospectively recorded evidence over at least
three consecutive cycles has confirmed that attacks occur
exclusively on day 1 ± 2 (i.e. days −2 to + 3) of menstruation
in at least two out of three menstrual cycles and at no other
times of the cycle
A1.1.2 Menstrually related migraine without aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.1
Migraine without aura and criterion B below
B. Documented and prospectively recorded evidence over at
least three consecutive cycles has confirmed that attacks
occur on day 1 ± 2 (i.e. days −2 to + 3) of menstruation in at
least two out of three menstrual cycles, and additionally at
other times of the cycle
ICHD, III edition, 2018
A1.1.1 Pure menstrual migraine without aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.1
Migraine without aura and criterion B below
B. Occurring exclusively on day 1 ± 2 (i.e. days −2 to + 3) of
menstruation in at least two out of three menstrual cycles
and at no other times of the cycle
A1.1.2 Menstrually related migraine without aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.1
Migraine without aura and criterion B below
B. Occurring on day 1 ± 2 (i.e. days −2 to + 3) of menstruation in
at least two out of three menstrual cycles, and additionally at
other times of the cycle
A1.2.0.1 Pure menstrual migraine with aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.2
Migraine with aura and criterion B below
B. Occurring exclusively on day 1 ± 2 (i.e. days −2 to + 3) of
menstruation in at least two out of three menstrual cycles and
at no other times of the cycle
A1.2.0.2 Menstrually related migraine with aura
A. Attacks, in a menstruating woman, fulfilling criteria for 1.2
Migraine with aura and criterion B below
B. Occurring on day 1 ± 2 (i.e. days −2 to + 3) of menstruation in
at least two out of three menstrual cycles, and additionally at
other times of the cycle
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Several attempts were made to manipulate the female
hormonal cycle to try to improve migraine [6, 11]. Studies
have investigated both MO, MA and migraine attacks re-
lated to menstruation [6, 11]. Additionally, as in users of
combined hormonal contraceptives (CHC) migraine attacks
mostly occur during the hormone free interval, studies also
evaluated how different estrogen or progestogen regimens
impact on the course of migraine [12–15]. CHC have been
associated with an increased risk of ischemic stroke in
women with migraine [16–21]. A working group including
headache experts, gynaecologists, stroke experts, and epide-
miologists developed a first consensus document about the
safety of hormonal contraceptives (HCs) in female migrai-
neurs of reproductive age [22]. According to the recom-
mendations of the European Headache Federation (EHF)/
European Society of Contraception and Reproductive
Health (ESCRH) consensus group, CHCs should not be
used in all women with MA and women with MO who
have additional risk factors. Progestogen-only hormonal
contraceptives (PHCs) can be safely considered in this
group of patients [22]. Currently, no formal guidelines spe-
cifically address hormonal treatment of migraine. The aim
of this consensus document is to provide recommendations
on the management of migraine with the use of estrogens
and progestogens in women of reproductive age.
Methods
In July 2017, EHF representatives selected a panel of inter-
national multidisciplinary experts in migraine and hormo-
nal contraception (HC). The panel was chosen to
represent the breadth of knowledge and experience and a
wide variety of opinions internationally. The aim of this
statement is to provide evidence-based guidance to clini-
cians about evidence-based options for the management
of migraine with exogenous estrogens and progestogens.
Review of the literature
A systematic review of the literature was performed ac-
cording to the Preferred Reporting Items for Systematic
Table 2 Diagnostic criteria of headache related to the use and to
the withdrawal of hormones according to the different editions of
the International Classification of Headache Disorders (ICHD)
ICHD, II edition, 2004
8.3.1 Exogenous hormone-induced headache
A. Headache or migraine fulfilling criteria C and D
B. Regular use of exogenous hormones
C. Headache or migraine develops or markedly worsens within
3 months of commencing exogenous hormones
D. Headache or migraine resolves or reverts to its previous pattern
within 3 months after total discontinuation of exogenous
hormones
8.4.3 Estrogen-withdrawal headache
A. Headache or migraine fulfilling criteria C and D
B. Daily use of exogenous estrogen for ≥3 weeks, which is
interrupted
C. Headache or migraine develops within 5 days after last use
of estrogen
D. Headache or migraine resolves within 3 days
ICHD, III edition, beta version, 2013
8.1.12 Headache attributed to exogenous hormone
A. Any headache fulfilling criterion C
B. Regular intake of one or more exogenous hormones
C. Evidence of causation demonstrated by both of the following:
1. Headache has developed in temporal relationship with the
commencement of hormone intake
2. One or more of the following:
a) headache has significantly worsened after an increase in
the dosage of the hormone
b) headache has significantly improved or resolved after a
reduction in the dosage of the hormone
c) headache has resolved after cessation of hormone intake
d) Not better accounted for by another ICHD-3 diagnosis
8.3.3 Estrogen-withdrawal headache
A. Headache or migraine fulfilling criterion C
B. Daily use of exogenous estrogen for ≥3 weeks, which has
been interrupted
C. Evidence of causation demonstrated by both of the following:
1. headache or migraine has developed within five days after
the last use of estrogen
2. headache or migraine has resolved within three days of its
onset
D. Not better accounted for by another ICHD-3 diagnosis
ICHD, III edition, 2018
8.1.10 Headache attributed to long-term use of non-headache
medication
A. Headache present on ≥15 days/month and fulfilling criterion C
B. Long-term use of a medication has occurred for purposes other
than the treatment of headache
C. Evidence of causation demonstrated by at least two of the
following:
1. headache has developed in temporal relation to the
commencement of medication intake
2. one or more of the following:
a) headache has significantly worsened after an increase in
dosage of the medication
b) headache has significantly improved or resolved after a
reduction in dosage of the medication
c) headache has resolved after cessation of the medication
3. the medication is recognized to cause head- ache, in at
least some people, during long- term use
D. Not better accounted for by another ICHD-3 diagnosis
Table 2 Diagnostic criteria of headache related to the use and to
the withdrawal of hormones according to the different editions of
the International Classification of Headache Disorders (ICHD)
(Continued)
8.3.3 Estrogen-withdrawal headache
A. Headache or migraine fulfilling criterion C
B. Daily use of exogenous estrogen for ≥3 weeks, which has
been interrupted
C. Evidence of causation demonstrated by both of the following:
1. headache or migraine has developed within five days after
the last use of estrogen
2. headache or migraine has resolved within three days of its
onset
D. Not better accounted for by another ICHD-3 diagnosis
Sacco et al. The Journal of Headache and Pain  (2018) 19:76 Page 3 of 21
Reviews and Meta-Analyses (PRISMA) guidelines [23].
We identified key papers on possible benefits of the use
of estrogens and progestogens in migraine. An initial lit-
erature search included all papers indexed on PubMed
and Scopus, from inception to October 23, 2017. The
systematic literature search was repeated at the end of
the consensus procedure to include all relevant papers
published until May 2018. The following search string
was used in both databases: “migraine AND (hormone
OR estrog* OR progest* OR contracept*)”. Two investi-
gators independently screened the titles and abstracts of
the publications identified to verify study eligibility. Lit-
erature screening was conducted in two steps. In the
first step, studies were excluded after reading the title
and the abstract for clear exclusion criteria. For studies
that passed the first step, the full text was assessed to
decide inclusion/exclusion. Disagreements were resolved
by consensus. The reference lists and Google Scholar ci-
tations of the selected articles were also screened. The
reasons for exclusion were recorded and summarized.
To summarize the search results, a data extraction sheet
was developed including the information of interest. Pa-
pers retrieved from the literature search as well as sum-
mary tables were shared among the panelists.
Data extraction
A general description of the study was extracted for each
publication. We extracted first author name and year of
publication, full citation, study design and setting, study
period, number of included patients, diagnostic criteria for
migraine, migraine type, treatments type, duration of obser-
vations and treatments, study results. Data extraction was
performed by a single researcher (SS) and double checked.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were selected prior to
the literature search.
We included studies that were 1) observational (retro-
spective and prospective) or interventional and in which
an estrogen and/or a progestogen drug was assessed as
possible treatment strategy for migraine; 2) were pub-
lished in English or in other languages if a reliable transla-
tion could be obtained; 3) using reliable criteria to
diagnose migraine; 4) assessing treatment with any form
of estrogen or progestogen; 5) reporting any outcome re-
ferring to migraine frequency, severity, duration, disability,
or use of drugs to treat the acute attacks before and after
treatment or in treated and untreated women. Whenever
different studies referring to the same population of pa-
tients were available we included the study with the largest
population or the longest follow-up. We excluded studies
1) with observational designs not reporting outcome be-
fore and after treatment or not comparing at least two
treatment strategies; 2) using estrogen or progestogen that
is no longer available or that is not considered a feasible
strategy; 3) performed in post-menopausal women.
Quality assessment
For each of the selected studies one author (SS) addressed
the quality of evidence. The quality of evidence was ad-
dressed according to GRADE approach for single studies
[24]. Randomized trials were considered as high quality of
evidence but their quality was downgraded in the case of
study limitations such as lack of allocation concealment,
lack of blinding, incomplete accounting for patients and
outcome events, selective outcome reporting bias, or other
limitations such as inadequate sample or lack of sample
size calculation [25]. Observational studies were consid-
ered as low quality of evidence but their quality was
upgraded if large magnitude effects, dose-response
gradient, if plausible confounding can increase confidence
in the estimate or other considerations [26].
Development of the expert consensus
The consensus process was performed according to the
Delphi method [27]. Development of the consensus state-
ment was organized in three rounds. In each round, pan-
elists were instructed not to discuss among themselves
and to send their feedback only to the facilitator (SS). Two
core panelists (SS, PM) developed a draft document con-
taining the statements. In round 1, the draft containing
the statements was sent by e-mail to all panelists accom-
panied by a clear explanation of the objectives of the study
and specific instructions. Panelists were asked to provide
free-text comments to all the statements and to suggest
additional items of relevance or questions to be answered.
Thereafter, the facilitator analysed answers obtained dur-
ing round 1 and drafted a revision version of the state-
ments with additional items. In round 2, a further draft of
the documents and of the statements was sent by e-mail
to all panelists. Each panelist was asked to report their
agreement for each statement and provide suggestions.
Panelists were also given the opportunity to identify fur-
ther additional items not included in the initial list of
statements. Responses were then analysed by the facilita-
tor and used to refine statements. In round 3, a revised
draft of the document and of the statements was devel-
oped and emailed to all panelists and the panelists were
asked again to revise and to express their agreement. The
panelists were also required to provide a rank order of the
statements. Response frequencies for each item were
calculated and entered anonymously into a database.
Statements to be included in the final document required
at least 80% agreement from the panel.
Drafting of the statements
Quality of evidence and strength of the recommendations
were rated according to the American College of Chest
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Physicians Task Force [28]. We also used the suggestions
provided by the ACCP referring to wording of the recom-
mendations. When making a strong recommendation we
used the terminology “We recommend…”, whereas when
making a weak recommendation, less definitive wording
was used, such as, “We suggest…”.
Results
For the present consensus statement, we adopt the diagnoses
of PMM or MRM as defined in the selected studies. The
term MM is used to encompass both PMM and MRM.
We found 21 studies which evaluated the effects of
estrogens and progestogens on headache in women of
reproductive age (Fig. 1) [12–15, 29–45].
In 11 studies treatment was specifically used for headache
prevention [12, 29–38], in 8 studies treatment effect on
headache was evaluated in women who required treatment
for contraception or medical reasons [13–15, 39–43], in 2
studies it was not specifically stated if treatment was pre-
scribed specifically for headache treatment or for other in-
dications [44, 45]. Five studies were performed in women
with MO or MA not necessarily related to menstruation
[12–14, 41, 43], 10 in MRM or MM [29–39, 43, 45], 4 in
PMM [29, 35, 38, 39], and 2 in women with and without
headache [15, 40].
Drugs which were evaluated to manage migraine in
women of reproductive age include the desogestrel
progestogen-only pill (POP) [13, 14, 41, 42], extended
regimen of oral CHCs [13–15, 30], oral CHCs with short-
ened pill-free interval [39, 43], oral CHCs with oral estro-
gen supplementation during the pill-free interval [44], oral
CHCs with estradiol supplementation with patch during
the pill-free interval [34], the combined hormonal contra-
ceptive patch [40], the combined hormonal contraceptive
vaginal ring [45], transdermal estradiol supplementation
with gel [31, 32, 35], transdermal estradiol supplementa-
tion with patch [29, 33, 37, 38], transdermal estradiol
supplementation with patch in women induced in
pharmacological menopause [12], and the subcutaneous
estrogen implant with cyclical progestogen [36].
Desogestrel progestogen-only pill
Four studies assessed the possible benefits of the deso-
gestrel POP in women with both MO and MA [41], MO
[13, 14], or MA [42]. All studies had an observational
design. The study drug was the desogestrel 75 μg/day
Fig. 1 Flow-chart for the systematic review. Search string: “migraine AND (hormone OR estrog* OR progest* OR contracept*)”. Date: 23-Oct-2017
Sacco et al. The Journal of Headache and Pain  (2018) 19:76 Page 5 of 21
Ta
b
le
3
St
ud
ie
s
ev
al
ua
tin
g
es
tr
og
en
an
d
pr
og
es
to
ge
n
st
ra
te
gi
es
in
w
om
en
of
re
pr
od
uc
tiv
e
ag
e
St
ud
y
St
ud
y
de
si
gn
(re
cr
ui
tm
en
t
pe
rio
d)
Se
tt
in
g
(d
ia
gn
os
tic
cr
ite
ria
)
W
om
en
in
cl
ud
ed
(n
)
Tr
ea
tm
en
t
D
ur
at
io
n
O
ut
co
m
e
Fi
nd
in
gs
D
es
og
es
tr
el
pr
og
es
to
ge
n-
on
ly
pi
ll
M
er
ki
-F
el
d,
20
17
[4
1]
Re
tr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l,
(2
00
9–
20
13
)
M
O
,M
A
(IC
H
D
-2
);
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
64
;6
dr
op
pe
d
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
D
es
og
es
tre
l7
5
μg
/d
ay
90
da
ys
of
ob
se
rv
at
io
n
an
d
90
da
ys
of
tr
ea
tm
en
t
M
ig
ra
in
e
da
ys
,
he
ad
ac
he
in
te
ns
ity
,
da
ys
w
ith
he
ad
ac
he
sc
or
e
3,
an
al
ge
si
c
us
e
Re
du
ce
d
m
ig
ra
in
e
da
ys
,
he
ad
ac
he
in
te
ns
ity
,d
ay
s
w
ith
he
ad
ac
he
an
d
us
e
of
pa
in
m
ed
ic
at
io
ns
N
ap
pi
,2
01
1
[4
2]
Pr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l
M
A
(IC
H
D
-2
);
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
30
;2
dr
op
pe
d-
ou
t
af
te
r
3-
m
on
th
(a
na
ly
si
s
on
tr
ea
tm
en
t
at
6
m
on
th
s)
D
es
og
es
tre
l7
5
μg
/d
ay
3
m
on
th
s
of
ob
se
rv
at
io
n
an
d
6
m
on
th
s
of
tr
ea
tm
en
t
M
ig
ra
in
e
at
ta
ck
s,
du
ra
tio
n
of
au
ra
,
du
ra
tio
n
an
d
se
ve
rit
y
of
he
ad
ac
he
pa
in
,
oc
cu
rr
en
ce
of
fo
ca
l
ne
ur
ol
og
ic
al
sy
m
pt
om
s
or
as
so
ci
at
ed
sy
m
pt
om
s,
an
al
ge
si
c
us
e
Re
du
ce
d
nu
m
be
r
of
m
ig
ra
in
e
at
ta
ck
s
in
pr
ev
io
us
C
O
C
s
us
er
s
an
d
no
nu
se
rs
D
es
og
es
tr
el
pr
og
es
to
ge
n-
on
ly
pi
ll
an
d
ex
te
nd
ed
re
gi
m
en
of
co
m
bi
ne
d
or
al
co
nt
ra
ce
pt
iv
es
M
or
ot
ti,
20
14
[1
4]
Re
tr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l
(2
00
9–
20
13
)
M
O
(IC
H
D
-2
);
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
53
;2
1
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
D
es
og
es
tre
l7
5
μg
/d
ay
vs
co
nt
in
uo
us
EE
20
μg
pl
us
or
al
de
so
ge
st
re
l1
50
μg
6
m
on
th
s
of
tr
ea
tm
en
t
(p
re
-t
re
at
m
en
t
ob
se
rv
at
io
n
pe
rio
d
no
t-
de
fin
ed
)
M
ig
ra
in
e
an
d
he
ad
ac
he
da
ys
,
he
ad
ac
he
in
te
ns
ity
,
da
ys
w
ith
he
ad
ac
he
sc
or
e
3,
pa
in
m
ed
ic
at
io
n,
tr
ip
ta
n
us
e,
qu
al
ity
of
lif
e
Re
du
ce
d
m
ig
ra
in
e
da
ys
,
he
ad
ac
he
da
ys
pa
in
in
te
ns
ity
,n
um
be
r
of
da
ys
w
ith
se
ve
re
pa
in
an
d
da
ys
w
ith
pa
in
m
ed
ic
at
io
n
in
PO
P
us
er
s;
re
du
ce
d
nu
m
be
r
of
he
ad
ac
he
da
ys
an
d
in
da
ys
w
ith
pa
in
m
ed
ic
at
io
n
in
C
O
C
s
us
er
s;
re
du
ce
d
nu
m
be
r
of
da
ys
w
ith
pa
in
m
ed
ic
at
io
n
in
th
e
PO
P
gr
ou
p
co
m
pa
re
d
to
th
e
C
O
C
gr
ou
p
M
or
ot
ti
20
14
[1
3]
Pr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l
(2
00
9–
20
13
)
M
O
(IC
H
D
-2
)a
nd
en
do
m
et
rio
si
s;
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
14
4;
27
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
de
so
ge
st
re
l7
5
μg
/
da
y
vs
se
qu
en
tia
l
(2
1/
7)
EE
20
μg
pl
us
de
so
ge
st
re
l1
50
μg
6
m
on
th
s
of
tr
ea
tm
en
t
(p
re
-t
re
at
m
en
t
ob
se
rv
at
io
n
pe
rio
d
no
t-
de
fin
ed
)
Se
ve
rit
y,
nu
m
be
r
an
d
du
ra
tio
n
of
m
ig
ra
in
e
at
ta
ck
s,
as
so
ci
at
ed
sy
m
pt
om
s
D
ec
re
as
ed
nu
m
be
r
an
d
in
te
ns
ity
of
m
ig
ra
in
e
at
ta
ck
s
in
PO
P
us
er
s
Ex
te
nd
ed
re
gi
m
en
of
co
m
bi
ne
d
or
al
co
nt
ra
ce
pt
iv
e
C
of
fe
e,
20
14
[3
0]
N
on
-r
an
do
m
iz
ed
,
op
en
-la
be
l*
M
RM
w
ith
ou
t
au
ra
(m
od
ifi
ed
IC
H
D
-2
cr
i-
te
ria
);
w
om
en
sp
ec
ifi
c-
al
ly
tr
ea
te
d
fo
r
he
ad
ac
he
32
;2
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
Ex
te
nd
ed
re
gi
m
en
of
EE
30
μg
+
le
vo
no
rg
es
tr
el
15
0
μg
2
cy
cl
es
of
ob
se
rv
at
io
n
an
d
16
8
da
ys
of
tr
ea
tm
en
t
H
ea
da
ch
e
se
ve
rit
y,
M
ID
A
S
sc
or
e,
an
al
ge
si
c
us
e
D
ec
re
as
e
in
da
ily
he
ad
ac
he
sc
or
es
Sacco et al. The Journal of Headache and Pain  (2018) 19:76 Page 6 of 21
Ta
b
le
3
St
ud
ie
s
ev
al
ua
tin
g
es
tr
og
en
an
d
pr
og
es
to
ge
n
st
ra
te
gi
es
in
w
om
en
of
re
pr
od
uc
tiv
e
ag
e
(C
on
tin
ue
d)
St
ud
y
St
ud
y
de
si
gn
(re
cr
ui
tm
en
t
pe
rio
d)
Se
tt
in
g
(d
ia
gn
os
tic
cr
ite
ria
)
W
om
en
in
cl
ud
ed
(n
)
Tr
ea
tm
en
t
D
ur
at
io
n
O
ut
co
m
e
Fi
nd
in
gs
Su
la
k,
20
07
[1
5]
Pr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l
W
om
en
w
ith
an
d
w
ith
ou
t
he
ad
ac
he
(n
o
IC
H
D
cr
ite
ria
;M
A
ex
cl
ud
ed
);
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
11
4;
12
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
EE
30
μg
pl
us
dr
os
pe
rin
on
e
3
m
g
St
an
da
rd
21
/7
-d
ay
cy
cl
es
fo
r
3
m
on
th
s
fo
llo
w
ed
by
a
16
8-
da
y
ex
te
nd
ed
pl
ac
eb
o-
fre
e
re
gi
m
en
Pr
es
en
ce
an
d
se
ve
rit
y
of
he
ad
ac
he
s,
an
al
ge
si
c
us
e,
im
pa
ct
of
he
ad
ac
he
s
on
w
or
k,
ho
us
ew
or
k,
so
ci
al
,r
ec
re
at
io
na
l,
an
d
fa
m
ily
ev
en
ts
Im
pr
ov
ed
he
ad
ac
he
sc
or
es
w
ith
th
e
ex
te
nd
ed
re
gi
m
en
C
om
bi
ne
d
or
al
co
nt
ra
ce
pt
iv
es
w
ith
sh
or
te
ne
d
pi
ll-
fre
e
in
te
rv
al
D
e
Le
o,
20
11
[3
9]
Ra
nd
om
iz
ed
,
pa
ra
lle
lg
ro
up
PM
M
(IC
H
D
-2
);
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
60
EE
20
μg
+
dr
os
pi
re
no
ne
3
m
g
21
ac
tiv
e
+
7
pl
ac
eb
o
vs
24
ac
tiv
e
+
4
pl
ac
eb
o
3
cy
cl
es
of
ob
se
rv
at
io
n
an
d
3
m
on
th
s
of
tr
ea
tm
en
t
D
ur
at
io
n
an
d
se
ve
rit
y
of
he
ad
ac
he
Bo
th
tr
ea
tm
en
ts
as
so
ci
at
ed
w
ith
re
du
ct
io
n
in
in
te
ns
ity
an
d
du
ra
tio
n
of
at
ta
ck
s;
gr
ea
te
r
re
du
ct
io
n
in
in
te
ns
ity
an
d
du
ra
tio
n
in
pa
tie
nt
s
ta
ki
ng
24
ac
tiv
e
+
7
pl
ac
eb
o
vs
21
ac
tiv
e
+
7
pl
ac
eb
o
N
ap
pi
,2
01
3
[4
3]
N
on
-r
an
do
m
iz
ed
,
op
en
-la
be
l
M
RM
(IC
H
D
-2
);
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
32
;4
dr
op
pe
d-
ou
t
(a
na
-
ly
si
s
on
tr
ea
tm
en
t
on
29
w
om
en
at
cy
cl
e
3
an
d
on
28
w
om
en
at
cy
cl
e
6)
Es
tr
ad
io
lv
al
er
at
e
+
di
en
og
es
t
pi
ll
us
in
g
an
es
tr
og
en
st
ep
-
do
w
n
an
d
pr
og
es
to
-
ge
n
st
ep
-u
p
ap
-
pr
oa
ch
26
da
ys
+
2
pl
ac
eb
o
3
cy
cl
es
of
ob
se
rv
at
io
n
an
d
6
cy
cl
es
of
tr
ea
tm
en
t
N
um
be
r
of
he
ad
ac
he
at
ta
ck
s,
nu
m
be
rs
of
ho
ur
s
of
he
ad
ac
he
pa
in
,n
um
be
r
of
ho
ur
s
of
se
ve
re
he
ad
ac
he
pa
in
,
as
so
ci
at
ed
ph
en
om
en
a,
an
al
ge
si
c
us
e
Re
du
ct
io
n
in
th
e
nu
m
be
r
an
d
du
ra
tio
n
of
m
ig
ra
in
e
at
ta
ck
s,
in
ho
ur
s
of
se
ve
re
pa
in
,a
nd
in
us
e
of
an
al
ge
si
cs
C
om
bi
ne
d
or
al
co
nt
ra
ce
pt
iv
es
w
ith
or
al
es
tr
ad
io
ls
up
pl
em
en
ta
tio
n
du
rin
g
th
e
pi
ll-
fre
e
in
te
rv
al
C
al
ho
un
,
20
04
[4
4]
Re
tr
os
pe
ct
iv
e
an
d
pr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l
M
O
(IC
H
D
-1
cr
ite
ria
)
as
so
ci
at
ed
w
ith
m
en
se
s;
in
di
ca
tio
n
no
t
sp
ec
ifi
ed
11
EE
20
μg
(d
ay
s
1–
21
)
an
d
co
nj
ug
at
ed
eq
ui
ne
es
tr
og
en
0.
9
m
g
(d
ay
s
22
–2
8)
1
cy
cl
e
of
tr
ea
tm
en
t
N
um
be
r
of
he
ad
ac
he
da
ys
,h
ea
da
ch
e
in
te
ns
ity
sc
or
e
D
ec
re
as
e
in
th
e
nu
m
be
r
of
he
ad
ac
he
da
ys
an
d
in
w
ei
gh
te
d
he
ad
ac
he
sc
or
e
C
om
bi
ne
d
or
al
co
nt
ra
ce
pt
iv
es
w
ith
es
tr
ad
io
ls
up
pl
em
en
ta
tio
n
w
ith
pa
tc
h
du
rin
g
th
e
pi
ll-
fre
e
in
te
rv
al
M
ac
G
re
go
r,
20
02
[3
4]
D
ou
bl
e-
bl
in
d,
pl
ac
eb
o-
co
nt
ro
lle
d,
ra
nd
om
iz
ed
,
cr
os
so
ve
r
st
ud
y
M
M
(IC
H
D
-1
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
14
Es
tr
ad
io
l5
0
μg
vs
pl
ac
eb
o
(a
ll
pa
tie
nt
s
w
er
e
on
co
m
bi
ne
d
ho
rm
on
al
co
nt
ra
ce
pt
iv
e
pi
ll)
2
cy
cl
es
of
ac
tiv
e
tr
ea
tm
en
t
an
d
2
cy
cl
es
of
pl
ac
eb
o
N
um
be
r
of
pi
ll-
fre
e
in
te
rv
al
s
w
ith
m
i-
gr
ai
ne
;n
um
be
r
of
da
ys
of
m
ig
ra
in
e;
se
ve
rit
y
of
m
ig
ra
in
e;
nu
m
be
r
of
da
ys
of
m
ig
ra
in
e
w
ith
as
so
ci
at
ed
sy
m
pt
om
s
Tr
en
d
to
w
ar
ds
re
du
ci
ng
th
e
fre
qu
en
cy
an
d
se
ve
rit
y
of
m
ig
ra
in
e
w
ith
th
e
pa
tc
h
Sacco et al. The Journal of Headache and Pain  (2018) 19:76 Page 7 of 21
Ta
b
le
3
St
ud
ie
s
ev
al
ua
tin
g
es
tr
og
en
an
d
pr
og
es
to
ge
n
st
ra
te
gi
es
in
w
om
en
of
re
pr
od
uc
tiv
e
ag
e
(C
on
tin
ue
d)
St
ud
y
St
ud
y
de
si
gn
(re
cr
ui
tm
en
t
pe
rio
d)
Se
tt
in
g
(d
ia
gn
os
tic
cr
ite
ria
)
W
om
en
in
cl
ud
ed
(n
)
Tr
ea
tm
en
t
D
ur
at
io
n
O
ut
co
m
e
Fi
nd
in
gs
C
om
bi
ne
d
ho
rm
on
al
co
nt
ra
ce
pt
iv
e
pa
tc
h
La
G
ua
rd
ia
,
20
05
[4
0]
Ra
nd
om
iz
ed
(2
00
2–
20
03
)
W
om
en
w
ith
an
d
w
ith
ou
t
he
ad
ac
he
;
w
om
en
w
ho
re
qu
ire
d
tr
ea
tm
en
t
fo
r
co
nt
ra
ce
pt
io
n
or
m
ed
ic
al
re
as
on
s
23
9
EE
20
μg
+
no
re
lg
es
tr
om
in
15
0
μg
pa
tc
h
Ex
te
nd
ed
(1
2
w
ee
kl
y
pa
tc
h,
1
pa
tc
h-
fre
e
w
ee
k,
3
w
ee
kl
y
pa
tc
h)
vs
cy
cl
ic
re
gi
m
en
(4
cy
cl
es
of
3
w
ee
kl
y
pa
tc
h
an
d
1
pa
tc
h-
fre
e
w
ee
k)
H
ea
da
ch
e
oc
cu
rr
en
ce
Le
ss
he
ad
ac
he
da
ys
in
th
e
pa
tc
h
on
th
an
in
th
e
pa
tc
h
of
fw
ee
ks
;d
ec
re
as
e
in
th
e
he
ad
ac
he
ra
te
du
rin
g
th
e
pa
tc
h-
on
w
ee
ks
ov
er
th
e
16
-w
ee
k
st
ud
y
pe
rio
d
C
om
bi
ne
d
ho
rm
on
al
co
nt
ra
ce
pt
iv
e
va
gi
na
lr
in
g
C
al
ho
un
,
20
12
[4
5]
Re
tr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l
(2
00
4–
20
10
)
M
ig
ra
in
e
w
ith
au
ra
+
M
RM
(m
od
ifi
ed
IC
H
D
cr
ite
ria
);
in
di
ca
tio
n
no
t
sp
ec
ifi
ed
28
;5
dr
op
pe
d
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
EE
15
μg
+
et
on
og
es
tr
el
0.
12
0
m
g
7.
8
m
on
th
s
(ra
ng
e:
2
to
30
m
on
th
s)
A
ur
a
fre
qu
en
cy
,
he
ad
ac
he
fre
qu
en
cy
an
d
in
te
ns
ity
,
re
so
lu
tio
n
of
M
RM
,
he
ad
ac
he
in
de
x
A
ur
a
fre
qu
en
cy
re
du
ce
d;
M
RM
el
im
in
at
ed
in
91
.3
%
of
su
bj
ec
ts
Tr
an
sd
er
m
al
es
tr
ad
io
ls
up
pl
em
en
ta
tio
n
w
ith
ge
l
de
Li
gn
ie
re
s,
19
86
[3
1]
Ra
nd
om
iz
ed
,
pl
ac
eb
o-
co
nt
ro
lle
d,
do
ub
le
-b
lin
d,
cr
os
so
ve
r
M
M
(N
o
IC
H
D
;m
ig
ra
in
e
w
ith
ou
t
au
ra
oc
cu
rr
in
g
ex
cl
us
iv
el
y
no
t
ea
rli
er
th
an
2
da
ys
be
fo
re
m
en
st
ru
at
io
n
an
d
no
la
te
r
th
an
th
e
la
st
da
y
of
th
e
m
en
se
s)
;w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
20
;2
dr
op
pe
d-
ou
t
Es
tr
ad
io
lg
el
1.
5
m
g
fo
r
7
da
ys
vs
pl
ac
eb
o
26
cy
cl
es
of
tr
ea
tm
en
t,
27
cy
cl
es
of
pl
ac
eb
o
O
cc
ur
re
nc
e,
du
ra
tio
n,
se
ve
rit
y
of
m
ig
ra
in
e
at
ta
ck
s,
as
pi
rin
us
e
Re
du
ct
io
n
in
th
e
oc
cu
rr
en
ce
an
d
se
ve
rit
y
of
at
ta
ck
s
an
d
in
th
e
us
e
of
as
pi
rin
D
en
ne
rs
te
in
,
19
88
[3
2]
Ra
nd
om
iz
ed
,
pl
ac
eb
o-
co
nt
ro
lle
d,
do
ub
le
-b
lin
d,
cr
os
so
ve
r
M
M
(N
o
IC
H
D
;r
eg
ul
ar
m
ig
ra
in
e
in
th
e
pa
ra
m
en
st
ru
um
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
22
;4
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
Es
tr
ad
io
lg
el
1.
5
m
g
fo
r
7
da
ys
vs
pl
ac
eb
o
2
cy
cl
es
of
tr
ea
tm
en
t,
2
cy
cl
es
of
pl
ac
eb
o,
an
d
1
cy
cl
e
of
fo
llo
w
-u
p
(n
o
tr
ea
tm
en
t)
O
cc
ur
re
nc
e
of
m
ig
ra
in
e,
m
od
er
at
e
to
se
ve
re
in
te
ns
ity
m
ig
ra
in
e,
an
al
ge
si
c
us
e
N
o
di
ffe
re
nc
e
in
th
e
oc
cu
rr
en
ce
of
at
ta
ck
s;
re
du
ct
io
n
of
m
od
er
at
e
to
se
ve
re
in
te
ns
ity
at
ta
ck
s
M
ac
G
re
go
r,
20
06
[3
5]
Ra
nd
om
iz
ed
,
do
ub
le
-b
lin
d,
pl
ac
eb
o-
co
nt
ro
lle
d,
cr
os
so
ve
r
PM
M
or
M
RM
(IC
H
D
-2
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
37
;2
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
Es
tr
ad
io
lg
el
1.
5
m
g
fo
r
6
da
ys
vs
pl
ac
eb
o
3
cy
cl
es
of
pl
ac
eb
o,
3
cy
cl
es
of
tr
ea
tm
en
t
M
ig
ra
in
e
da
ys
an
d
se
ve
rit
y,
du
ra
tio
n
of
at
ta
ck
s,
as
so
ci
at
ed
sy
m
pt
om
s,
oc
cu
rr
en
ce
of
au
ra
,
an
al
ge
si
c
us
e
Re
du
ct
io
n
in
m
ig
ra
in
e
da
ys
an
d
at
ta
ck
s
se
ve
rit
y;
in
cr
ea
se
in
m
ig
ra
in
e
oc
cu
rr
en
ce
in
th
e
5
da
ys
im
m
ed
ia
te
ly
af
te
r
es
tr
ad
io
l
us
e
Tr
an
sd
er
m
al
es
tr
ad
io
ls
up
pl
em
en
ta
tio
n
w
ith
pa
tc
h
A
lm
en
-
C
hr
is
te
ns
so
n,
20
11
[2
9]
Ra
nd
om
iz
ed
,
pl
ac
eb
o-
co
nt
ro
lle
d,
do
ub
le
-b
lin
d
cr
os
so
ve
r
PM
M
(IC
H
D
-2
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
38
;6
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
Es
tr
ad
io
l1
00
μg
vs
pl
ac
eb
o
2
w
ee
ks
of
tr
ea
tm
en
t
fo
r
3
cy
cl
es
fo
r
pl
ac
eb
o
an
d
3
cy
cl
es
fo
r
ac
tiv
e
tr
ea
tm
en
t
N
um
be
r,
se
ve
rit
y
an
d
in
te
ns
ity
of
m
ig
ra
in
e
at
ta
ck
s
N
o
di
ffe
re
nc
es
be
tw
ee
n
ac
tiv
e
tr
ea
tm
en
t
an
d
pl
ac
eb
o
Sacco et al. The Journal of Headache and Pain  (2018) 19:76 Page 8 of 21
Ta
b
le
3
St
ud
ie
s
ev
al
ua
tin
g
es
tr
og
en
an
d
pr
og
es
to
ge
n
st
ra
te
gi
es
in
w
om
en
of
re
pr
od
uc
tiv
e
ag
e
(C
on
tin
ue
d)
St
ud
y
St
ud
y
de
si
gn
(re
cr
ui
tm
en
t
pe
rio
d)
Se
tt
in
g
(d
ia
gn
os
tic
cr
ite
ria
)
W
om
en
in
cl
ud
ed
(n
)
Tr
ea
tm
en
t
D
ur
at
io
n
O
ut
co
m
e
Fi
nd
in
gs
G
ui
do
tt
i,
20
07
[3
3]
Pr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l
M
M
(IC
H
D
-2
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
38
(1
0
tr
ea
te
d
w
ith
EE
)
Es
tr
ad
io
l2
5
μg
vs
fro
va
tr
ip
ta
n
vs
na
pr
ox
en
so
di
um
1
cy
cl
e
of
tr
ea
tm
en
t
(6
da
ys
be
fo
re
ex
pe
ct
ed
m
en
st
ru
at
io
n)
N
um
be
r
an
d
se
ve
rit
y
of
m
ig
ra
in
e
at
ta
ck
s
Re
du
ct
io
n
in
nu
m
be
r
of
m
ig
ra
in
e
at
ta
ck
s
an
d
se
ve
rit
y
of
at
ta
ck
s
w
ith
fro
va
tr
ip
ta
n
th
an
w
ith
es
tr
ad
io
lo
r
na
pr
ox
en
so
di
um
Pr
ad
al
ie
r,
19
94
[3
7]
Ra
nd
om
iz
ed
,
op
en
-la
be
ls
tu
dy
M
M
(IC
H
D
-1
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
24
Es
tr
ad
io
l2
5
μg
vs
es
tr
ad
io
l1
00
μg
1
cy
cl
e
of
ob
se
rv
at
io
n,
2
cy
cl
es
of
tr
ea
tm
en
t
O
cc
ur
re
nc
e
an
d
se
ve
rit
y
of
M
M
Re
du
ct
io
n
in
nu
m
be
r
of
at
ta
ck
s
w
ith
th
e
hi
gh
er
do
se
Sm
ite
,1
99
3
[3
8]
Ra
nd
om
iz
ed
,
pl
ac
eb
o-
co
nt
ro
lle
d
(1
98
9–
19
90
)
PM
M
(IC
H
D
-1
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
20
Es
tr
ad
io
l5
0
μg
vs
pl
ac
eb
o
6
da
ys
of
tr
ea
tm
en
t
fo
r
3
cy
cl
es
(e
st
ra
di
ol
-
pl
ac
eb
o-
es
tr
ad
io
lo
r
pl
ac
eb
o-
es
tr
ad
io
l-
pl
ac
eb
o)
Pr
es
en
ce
,d
ur
at
io
n,
se
ve
rit
y
of
m
ig
ra
in
e
at
ta
ck
s,
an
al
ge
si
c
us
e
N
o
di
ffe
re
nc
es
be
tw
ee
n
ac
tiv
e
tr
ea
tm
en
t
an
d
pl
ac
eb
o
Tr
an
sd
er
m
al
es
tr
ad
io
ls
up
pl
em
en
ta
tio
n
w
ith
pa
tc
h
in
w
om
en
in
du
ce
d
in
ph
ar
m
ac
ol
og
ic
al
m
en
op
au
se
M
ar
tin
,2
00
3
[1
2]
Ra
nd
om
iz
ed
,
pl
ac
eb
o-
co
nt
ro
lle
d,
pa
ra
lle
l
gr
ou
p
(1
99
7–
20
01
)
M
O
,M
A
(IC
H
D
-1
);
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
23
;2
dr
op
pe
d-
ou
t
(o
n
tr
ea
tm
en
t
an
al
ys
is
)
go
se
re
lin
3.
6
m
g
im
pl
an
t
w
ith
es
tr
ad
io
l1
00
μg
pa
tc
he
s
ev
er
y
6
da
ys
vs
go
se
re
lin
3.
6
m
g
im
pl
an
t
w
ith
pl
ac
eb
o
pa
tc
he
s
1
le
ad
-in
m
on
th
,
2.
5
m
on
th
s
of
pl
ac
eb
o,
1
m
on
th
of
go
se
re
lin
in
je
ct
io
n,
2
m
on
th
s
of
ra
nd
om
iz
at
io
n
H
ea
da
ch
e
in
de
x,
di
sa
bi
lit
y
in
de
x,
he
ad
ac
he
fre
qu
en
cy
an
d
se
ve
rit
y
Re
du
ce
d
he
ad
ac
he
an
d
di
sa
bi
lit
y
in
de
x
an
d
in
he
ad
ac
he
fre
qu
en
cy
in
th
e
G
RH
ag
on
is
t/
es
tr
ad
io
l
gr
ou
p
Su
bc
ut
an
eo
us
es
tr
og
en
im
pl
an
t
pl
us
cy
cl
ic
al
pr
og
es
to
ge
n
M
ag
os
,1
98
3
[3
6]
Re
tr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l;
w
om
en
sp
ec
ifi
ca
lly
tr
ea
te
d
fo
r
he
ad
ac
he
M
M
w
ith
an
d
w
ith
ou
t
au
ra
(N
o
IC
H
D
;a
tt
ac
ks
im
m
ed
ia
te
ly
be
fo
re
or
du
rin
g
m
en
st
ru
at
io
n)
24
Es
tr
ad
io
l(
10
0
m
g
th
en
de
cr
ea
se
d
to
50
m
g)
+
no
re
th
is
te
ro
ne
5
m
g/
da
y
fo
r
7
da
ys
pe
r
m
on
th
2.
5
ye
ar
s
(m
ea
n
du
ra
tio
n)
of
tr
ea
tm
en
t
Im
pr
ov
em
en
t
of
m
en
st
ru
al
m
ig
ra
in
e
95
.8
%
of
pa
tie
nt
s
w
ith
im
pr
ov
em
en
t
in
M
M
;4
6%
be
ca
m
e
he
ad
ac
he
-fr
ee
an
d
37
.5
%
ga
in
ed
al
m
os
t
co
m
pl
et
e
sy
m
pt
om
at
ic
re
lie
f
M
O
m
ig
ra
in
e
w
ith
ou
t
au
ra
,M
A
m
ig
ra
in
e
w
ith
au
ra
,I
CH
D
In
te
rn
at
io
na
lC
la
ss
ifi
ca
tio
n
of
H
ea
da
ch
e
D
is
or
de
rs
,E
E
et
hi
ny
le
st
ra
di
ol
PM
M
pu
re
m
en
st
ru
al
m
ig
ra
in
e,
M
RM
m
en
st
ru
al
ly
re
la
te
d
m
ig
ra
in
e,
M
M
m
en
st
ru
al
m
ig
ra
in
e
Sacco et al. The Journal of Headache and Pain  (2018) 19:76 Page 9 of 21
oral pill in all studies. All the studies were performed in
the setting of a reproductive clinic in women who were
prescribed with the study treatments for contraception
or medical reasons. Details of the studies are reported in
Table 3. The quality of evidence was rated as low for all
the available studies (Table 4).
Merki-Feld et al. performed a retrospective, observa-
tional study in 64 women with MO and MA [41]. The
diagnosis was made according to ICHD-2 criteria. There
was a 90-day observation period followed by 90 days of
treatment. Patients were stratified according to the use of
CHCs before inclusion. Treatment with desogestrel was
associated with a significant reduction in migraine days
(6.2 ± 4.2 vs 5.2 ± 5.3; P = 0.001 in previous CHCs non
users and 5.9 ± 4.1 vs 3.5 ± 3.3; P = 0.001 in previous
CHCs users), headache intensity (17.2 ± 8.0 vs 12.7 ± 7.7;
P = 0.001 in previous CHCs non users and 17.3 ± 9.3 vs
11.6 ± 8.9; P = 0.001 in previous CHCs users), days with
headache score 3 (6.0 ± 5.8 vs 2.8 ± 2.7; P = 0.004 in previ-
ous CHCs non users and 6.7 ± 7.4 vs 2.8 ± 3.9; P = 0.001
in previous CHCs users), use of triptans (16.9 ± 17.8 vs
13.2 ± 12.2; P = 0.2 in previous CHCs non users and
9.6 ± 11.2 vs 6.1 ± 7.3; P = 0.003 in previous CHCs users),
and MIDAS score (30.2 ± 21.8 vs 13.9 ± 15.3; P = 0.001 in
previous CHCs non users and 34.7 ± 43.9 vs 20.0 ± 41.4;
P = 0.001 in previous CHCs users).
Nappi et al. performed a prospective, observational
study in 30 women with MA [42]. The diagnosis was
made according to ICHD-2 criteria. There was a 3-month
observation period followed by 6 months of treatment.
The authors found a significant reduction in the number
of migraine attacks (P < 0.001) and of aura symptoms
(P < 0.02) with treatment. There was no benefit on the
duration of headache pain and on analgesic consump-
tion. Benefits in the reduction of migraine attacks
were evident in both users (3.9 ± 1.0 vs 2.9 ± 0.8; P <
0.001) and non-users (3.2 ± 0.9 vs 2.6 ± 1.3; P < 0.02) of
CHCs before study entry, whereas benefits on aura
were evident in users of CHCs only (duration of total
symptoms of aura 33.6 ± 23.3 min vs 18.6 ± 18.0 min;
P < 0.02).
Morotti et al. performed a retrospective, observational
study in 31 women with MO [14]. The diagnosis was made
according to ICHD-2 criteria. A pre-study observation
period was not defined; there was a 6-month treatment
period. The authors compared pre- and post-treatment
periods and additionally compared POP treatment with an
extend oral CHC regimen. The authors found that treat-
ment with desogestrel was associated with a reduction in
migraine days per month (5.5 ± 2.6 vs 3.5 ± 1.2; P < 0.001),
headache days (3.6 ± 1.5 vs 2.7 ± 1.1; P = 0.010), pain inten-
sity (14.4 ± 5.4 vs 10.3 ± 2.4; P = 0.002), number of days with
severe pain (4.9 ± 1.9 vs 3.3 ± 1.4; P < 0.001) and days with
pain medication (6.1 ± 1.4 vs 3.5 ± 1.4; P < 0.001).
Morotti et al. performed an additional prospective ob-
servational study in 62 women with MO [13]. The diag-
nosis was made according to ICHD-2 criteria. A
pre-study observation period was not defined; there was
Table 4 Assessment for rating up the quality of evidence for
individual observational studies
Criteria for rating up the quality of evidence from observational studies were
selected and addresses according to the GRADE recommendations (Guyatt et
al. [26]). The red dot indicates that the study does not meet quality of
evidence criterion
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a 6-month treatment period. The authors compared pre-
and post-treatment periods and additionally compared
POP treatment with an extend oral CHC regimen. The
authors found that treatment with desogestrel was asso-
ciated with a reduction in severity on a four-point (0–3)
scale (2.5 ± 0.5 vs 1.8 ± 0.7; P < 0.001), number (6.2 ± 2.9
vs 4.9 ± 1.7; P = 0.005), and duration (20.5 ± 7.9 vs 15.9 ±
4.4; P < 0.001) of migraine attacks.
Side effects associated with desogestrel use included
higher headache frequency, prolonged bleeding, spot-
ting, and acne [13, 14, 41, 42].
In conclusion, current evidence for POPs is limited as it
comes solely from observational studies performed in the
gynecological setting and refers only to a single agent (deso-
gestrel pill). Available data indicate that treatment with oral
desogestrel may be associated with improvement in migraine
in women with MO and MA. However, treatment has been
tested only in those who need it for contraception or medical
reasons. The available data refer to the desogestrel pill only
and no information is available for the norethisterone or
levonorgestrel pills or for progestogen-only non-oral
methods such as subdermal implant, depot-injection, and
levonorgestrel-releasing intrauterine system. As desogestrel
is safe in terms of cardiovascular risk it is a possible option
even for women with MA or women with MO and add-
itional vascular risk factors [22]. Recommendations for the
desogestrel POP are reported in Table 5.
Extended regimen of combined oral contraceptives
Four studies assessed the possible benefits of extended
regimen of oral CHC in women MRM without aura [30],
in women with MO [13, 14] and in women with and with-
out headache (excluding women with MA) [15]. Two of
those studies were those by Morotti et al. which were con-
sidered for data about POP. All studies had an observa-
tional design. The study drugs were ethinylestradiol (EE)
30 μg/day + levonorgestrel 150 μg/day [30], EE 20 μg/day
+ desogestrel 150 μg/day [13, 14], and EE 20 μg/day +
drospirenone 3 mg/day [15]. One study was performed
in the setting of gynecology practice in women with-
out an expressed need for HC and thus treatment was
specifically prescribed for headache management [30].
Another three trials were conducted in the setting of a
reproductive clinic in women who were prescribed
with treatments for contraception or medical reasons
[13–15]. Details of the studies are reported in Table 3.
The quality of evidence was rated as low for all the
available studies (Table 4).
Coffee et al. performed a cross-over study in 32 women
with MRM without aura [30]. The diagnosis was made ac-
cording to modified ICHD-2 criteria. The pre-treatment
observation period was 2 menstrual cycles. During the ob-
servation period, some of the included women were on
21/7 oral CHC whereas others were not on HC. During
the extended HC regimen women were randomized to
frovatriptan or placebo for the treatment of acute attacks.
The authors reported a decrease in average headache
scores (0–10 scale) during the extended HC regimen as
compared to baseline (1.29±0.10 vs 1.10±0.14; P = 0.034).
The findings were consistent in women taking or not tak-
ing HCs during the observation period. Users of extended
HC regimen also had a decrease in MIDAS scores as com-
pared to baseline.
Morotti et al. performed a retrospective, observational
study in 22 women with MO [14]. The authors found
that the extended regimen of CHC was associated with a
reduction in the number of headache days (3.1 ± 0.9 vs
2.4 ± 1.9; P = 0.029) and in days with pain medication
(6.1 ± 1.4 vs 4.2 ± 1.3; P = 0.037) but not with a reduction
in pain intensity or use of acute medications.
Morotti et al. performed a prospective observational
study in 82 women [13]. The authors compared pre-
and post-treatment periods. The authors found that
the extended regimen of combined oral contraceptive
was associated with a reduction in the duration of
migraine attacks (22.7 ± 9.0 vs 18.9 ± 6.0; P = 0.007)
but not in reduction of pain severity and number of
attacks.
Sulak et al. performed a prospective observational
study in 114 women with and without headache [15].
Women with MA were excluded. The diagnosis was not
made according to ICHD-2 criteria. The authors com-
pared a standard 21/7 day pill cycle for 3 months
followed by a 168-day extended placebo-free regimen.
The authors found that during the first 28 days of the
extended placebo-free regimen, daily headache scores
(measured with the Penn Daily Symptom Rating)
decreased from 0.5 (standard error [SE] 0.05) to 0.3
(SE 0.04; P < 0.0001) and average number of daily
pain pills decreased from 0.6 (SE 0.08) to 0.3 (SE 0.05;
P = 0.003) compared with the standard 21/7 regimen. The
difference persisted throughout the remainder of the
168-day regimen.
Reported side effects of the extended oral CHC in-
cluded irregular bleeding, breast tenderness and mood
swings [13–15].
In conclusion, current evidence on the use of extended
oral CHCs regimens in women with migraine is limited
as it comes from observational studies performed in the
gynecological setting [13–15]. In only one study only
treatment was specifically used for headache [30]. Avail-
able data refer to EE 30 μg + levonorgestrel 150 μg [30],
oral EE 20 μg + oral desogestrel 150 μg for 6 months
[13, 14], and to EE 30 μg + drospirenone 3 mg for
160 days [15]. One study only provided comparison of
the extended regimen with conventional 21/7 regimen.
This study included women with and without headache
and supported greater benefits of the extended regimen
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over the conventional one. No studies evaluated whether
the use of extended regimens in women who are in the
conventional 21/7 regimen and who experience attacks
during the pill-free period may reduce the burden of
those attacks. As available data point toward possible
benefits of extended regimen of CHCs in women with
MO, this possibility should be considered in women
who require the use of CHCs. Recommendations for the
extended regimen of combined oral contraceptives are
reported in Table 5.
Desogestrel progestogen-only pill vs extended regimen
of combined oral contraceptives
Two of the studies which addressed, in women with
MO, the POP and extended regimen of oral CHC, also
compared the two treatments [13, 14]. The study drugs
were desogestrel 75 μg/day oral pill versus EE 20 μg/day
+ desogestrel 150 μg/day. Details of the studies are re-
ported in Table 3. The quality of evidence was rated as
low for all the available studies (Table 4).
Morotti et al. compared data of 31 women with MO
who were treated with desogestrel 75 μg/day and 22
women with MO who were treated with continuous
ethinylestradiol (EE) 20 μg/day + desogestrel 150 μg/day
[14]. The authors found that desogestrel 75 μg/day as
compared to the continuous EE 20 μg/day + desogestrel
150 μg/day was associated with a reduction in the num-
ber of days with pain medication (3.5 ± 1.4 vs 4.5 ± 1.5;
P = 0.044). There was no difference between the two
group in migraine days, headache days, headache inten-
sity, days with headache score 3 and triptan use.
Morotti et al. compared data of 62 women with MO who
were treated with desogestrel 75 μg/day and 82 women with
MO who were treated with continuous EE 20 μg/day + deso-
gestrel 150 μg/day for 6 months [13]. The authors found that
desogestrel 75 μg/day as compared to the continuous EE 20
μg/day + desogestrel 150 μg was associated with a reduction
in pain severity (1.8 ± 0.7 vs 2.2 ± 0.5; P < 0.001), duration of
attacks (15.9 ± 4.4 vs 18.9 ± 6.0; P < 0.001) and number of
attacks (4.9 ± 1.7 vs 5.9 ± 2.1; P < 0.001).
In conclusion, current evidence referring to the bene-
fits of POP as compared to extended regimen of oral
CHD are limited. The available data come from two
observational studies performed in the gynecological
setting and refer only to desogestrel versus EE + desoges-
trel. Available data suggest more benefit from desoges-
trel over the oral CHC but evidence is too preliminary
to draw firm conclusions.
Combined oral contraceptives with shortened pill-free
interval
Two studies assessed the role of CHC with shortened
pill-free interval in women with MO associated with
menstruation [43] or in women with PMM [39]. One
study had an interventional design [39]; one was obser-
vational [43]. Study regimens were EE 20 μg + drospire-
none 3 mg for 24 days + 4 placebo days versus EE 20 μg
+ drospirenone 3 mg for 21 days + 7 placebo days [39],
and estradiol valerate + dienogest using an estrogen
step-down and progestogen step-up approach for 26 days
+ 2 placebo days [43]. The two studies were performed
in the setting of a reproductive clinic in women who
were prescribed treatment for contraception or medical
reasons [39, 43]. Details of the studies are reported in
Table 3. The quality of evidence was rated as low for all
the available studies (Table 4 and Table 6).
De Leo et al. performed a randomized, parallel group
study in 60 women with PMM without aura [39]. The
diagnosis was made according to ICHD-2 criteria. Treat-
ment duration was 3 months and before enrollment
headaches were tracked for 3 menstrual cycles. Both
treatment with the conventional and the shortened
pill-free interval were associated with reduction in head-
ache intensity and days of migraine as compared to
Table 6 Rating of the quality of evidence for individual
interventional trials
39
31
32
40
34
35
37
38
Quality of evidence for the individual randomized trials was rated according to
the GRADE recommendations (Guyatt et al. [25]. The green dot indicates that
the study meets quality of evidence criterion and the red dot that the study
does not meet quality of evidence criterion. Where studies did not report
information about the individual criterion, this was considered as not meet
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baseline observation. Treatment with the shortened
pill-free interval was associated with significantly greater
reduction in the intensity and duration of MM as com-
pared to 21/7 HC. Improvements were observed from
the first cycle and increased over the study period. Of
note this study did not provide numbers to quantify ben-
efits of treatment but results were available as figures
only. No side effects were reported in the study.
Nappi et al. performed an open-label observational study
in 32 women with MRM [43]. The diagnosis was made ac-
cording to ICHD-2 criteria. Pre-treatment observation
period was 3 menstrual cycles; duration of treatment was 6
menstrual cycles. The study included a group of women
who had never used CHCs and a group who had used them
and stopped them because of exacerbation of MRM at least
3 months before enrollment. After treatment, the number
of migraine attack days was reduced from 2.7 ± 0.9 days at
baseline to 2.2 ± 0.7 (P < 0.001) at cycle 3 and 2.0 ± 0.7 (P <
0.001) at cycle 6. Similarly, the duration of headaches was
reduced from 44.7 ± 13.5 h at baseline to 24.7 ± 10.1 h (P <
0.001) at cycle 3 and remained reduced 24.1 ± 9.2 h (P <
0.001) at cycle 6. The numbers of hours of severe pain was
reduced from the baseline of 21.9 ± 7.4 h to 15.4 ±
4.9 h (P < 0.001) at cycle 3 and continued at the lower
levels of 15.0 ± 5.0 h (P < 0.001) at cycle 6. A significant
reduction in the number of analgesics use was observed
from baseline of 4.7 ± 1.1 to 3.3 ± 0.7 (P < 0.001) at
cycle 3, which dropped even lower to 2.9 ± 0.6 by cycle
6 (P < 0.001 cycle 3 versus cycle 6). Benefits were ob-
served in both users and non-users of combined oral
contraceptives before study entry. The only side effect
reported in this study was spotting. Some women in
this study had to stop the HC because of worsening of
the migraine.
In conclusion, current evidence on the use of oral
CHCs with shortened pill-free interval in women with
migraine is limited. Available studies included PMM or
MRM. One study suggested superiority of the shortened
pill-free interval treatment over the conventional one
[39]. Available studies are heterogeneous referring to
adopted regimen and there is no evidence which may in-
dicate superiority of one regimen over the other possibil-
ities. Additionally, evidence mostly support the use of
CHCs with shortened pill-free interval in women who
need them for contraceptive or gynecological reasons.
But there is not enough evidence to use this treatment
solely for the management of migraine. The extended
regimen is safe and not associated with significant ad-
verse events, but it is important to note that some
women with migraine may be particularly sensitive to
hormonal administration and need to stop treatment be-
cause worsening of headache [43]. It may be difficult to
establish if the worsening is really related to treatment
or rather to natural fluctuations in the migraine course
nor it is clear if improvements can be observed with
continuation of treatment. Recommendations for the
combined oral contraceptives with shortened pill-free
interval are reported in Table 5.
Combined oral contraceptives with oral estrogen
supplementation during the pill-free interval
One observational study assessed the role of CHC with
oral estrogen supplementation during the pill-free inter-
val in women with MO associated with menstruation
and women with migraine associated with CHC with-
drawal bleeding [44]. The study regimen was EE 20 μg
(days 1–21) + conjugated equine estrogens 0.9 mg (days
22–28). In this study patients were recruited both from
a headache center and from gynecology practice.
Calhoun performed a cross-over prospective and retro-
spective study in 11 women with MO associated with men-
struation or withdrawal bleeds. The diagnosis was made
according to modified ICHD-2 criteria. Duration of active
treatment was for one cycle only. During the pre-treatment
observational phase some of the included patients were not
using hormone therapy (n= 3), whereas most of them (n=
8) were on hormonal treatment. There was heterogeneity re-
garding doses, duration, and type of treatments. The dur-
ation of the observational period before intervention was not
reported. The authors found that all patients achieved a 50%
reduction in the number of headache days. Mean number of
headache days per month was 7.6 at baseline and 1.6 after
treatment (76.3% reduction). Also headache intensity score
substantially improved (77.9% decrease). No information on
side effects and adverse events was reported.
In conclusion, evidence on the use of oral CHCs with
oral estrogen supplementation during the pill-free inter-
val in women with migraine is limited to a single unreli-
able study. Recommendations for the combined oral
contraceptives with oral estrogen supplementation dur-
ing the pill-free interval are reported in Table 5.
Combined oral contraceptives with estradiol
supplementation with patch during the pill-free interval
One interventional study assessed the possible benefits of
transdermal estradiol supplementation with patch in
women with migraine during the pill-free interval of com-
bined oral contraceptives [34]. The study drug was 50 μg
estradiol patch specifically prescribed for headache man-
agement. Details of the study is reported in Table 3. The
quality of evidence was rated as low (Table 4 and Table 6).
MacGregor et al. performed a double-blind,
placebo-controlled, randomized, cross-over study in 14
women [34]. The authors addressed as active treatment
estradiol 50 μg/24 h transdermal patch. The active treat-
ment was compared with placebo. All women included
in the study were taking a CHC pill. The estradiol patch
was used for 2 cycles during the pill-free week and the
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placebo patch was used for additional 2 cycles during
the pill-free week. Authors were unable to meet their re-
cruitment target of 20 women. There was no significant
reduction in number of pill-free intervals with migraine,
number of days of migraine, severity of migraine, num-
ber of days with migraine with associated symptoms.
Adverse events related to transdermal estradiol supple-
mentation were changes in withdrawal bleeding patterns
reported by three women.
As these data from a single study show no benefit of estra-
diol supplementation with patches on migraine occurrence
during the pill-free interval, this cannot be considered as a
possible therapeutic option. Recommendations for the trans-
dermal estrogen patch supplementation during the pill-free
interval are reported in Table 5.
Combined hormonal contraceptive patch
One study assessed the possible benefits of the CHC
patch in women with and without headache [40]. The
study had an interventional design. The study drug was
EE 20 μg + norelgestromin 150 μg/24 h patch. The study
was performed in the setting of reproductive clinics in
women who were prescribed with the study treatments
and not specifically for headache management. Details
of the study are reported in Table 3. The quality of evi-
dence was rated as low for this study (Table 6).
LaGuardia et al. performed a prospective observational
study in 239 women with and without headache; women
with MA were excluded [40]. The authors compared a cyc-
lic regimen (4 cycles of 3 weekly patch applications and 1
patch-free week) with an extended regimen (12 weekly
patch applications, 1 patch-free week, 3 weekly patch appli-
cations). The authors found that, across both regimens, the
mean number of headache days per week were 0.63 when
the patch was on and 1.19 when the patch was off
(P < 0.001). Moreover, the headache rate during the
patch-on weeks in both regimens decreased significantly
over the 16-week study period (P = 0.0002); this reduction
was consistent for the two regimens. The study did not re-
port the side effects associated with the use of the patch.
In conclusion, data referring to the effect of CHC patch
on migraine are very limited. One study only evaluated
the effect of the CHC patch on headache course [40]. Data
from this study suggested that there is a relationship be-
tween hormone withdrawal and headache occurrence.
The mean headache days was higher during the patch-off
week. In the patch-off week following the extended regi-
men the increase in headache frequency did not exceed
that seen at baseline. Recommendations for the combined
hormonal contraceptive patch are reported in Table 5.
Combined hormonal contraceptive vaginal ring
One study assessed the possible benefits of the vaginal ring
in women with MA associated with menstruation [45]. The
study had an observational design. The study drug was EE
15 μg + etonogestrel 0,120 mg vaginal ring. The study was
performed in the setting of subspecialty clinic devoted to
hormonal issues in women’s headaches. It is not clearly in-
dicated if treatment was prescribed for contraception or
medical reasons or specifically for headache management.
Details of the study are reported in Table 3. The quality of
evidence was rated as low for this study (Table 4).
Calhoun et al. performed a retrospective, observational
study in 28 women with MA associated with menstru-
ation [45]. The diagnosis was made according to modi-
fied ICHD-2 criteria. Eight women used the ring
continuously without interruption, 15 used the ring for
12 consecutive weeks, followed by 1 week of 0.075 mg
transdermal 17β estradiol patches, 5 stopped the ring.
Ten of the women were already taking HCs before en-
rollment. Headache frequency was monitored with diar-
ies. Pre- and post-treatment observation periods were
not defined and authors did not provide any information
about migraine frequency, severity or disability before
and after treatments. The authors reported that, after a
mean observation of 7.8 months, the use of vaginal ring
eliminated MRM in 91.3% of subjects. They further re-
ported single patient data showing the course of aura
over the study period and those data suggest improve-
ments in aura in most of the included patients. Five of
the included patients discontinued treatment for nausea
(n = 2), for ring expulsion (n = 2), and for facial swelling
and abdominal pain (n = 1).
In conclusion, current evidence on the use of CHC va-
ginal ring in women with migraine is very limited. There
are not enough data to clarify if the use of CHCs by va-
ginal ring may improve migraine. The only available
study did not provide sufficiently rigorous information
to fully understand benefits and disadvantages of treat-
ment. Additionally, the study included women with MA,
a condition in which the use contraceptives containing
estrogens are contraindicated because concerns over a
possible increase in the risk of ischemic stroke [22]. No
ischemic strokes were reported during the study period
but the number of included patients was low and the
duration of follow-up was too short to draw conclusions.
Recommendations for the combined hormonal contra-
ceptive vaginal ring are reported in Table 5.
Transdermal estradiol supplementation with gel
Three studies assessed the role of transdermal estradiol sup-
plementation with gel in women with MM [31, 32] and in
women with PMM or MRM [35]. All studies had an inter-
ventional design. Two studies were randomized [32, 35]. The
study drug was estradiol gel 1.5 mg for 6 [35] or 7 days [31,
32]. In all the studies, transdermal estradiol gel was evaluated
against placebo [31, 32, 35]. In all the studies treatment was
specifically prescribed for headache management. Details of
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the study are reported in Table 3. The quality of evidence
was rated as low for the two studies [31, 32], high for one of
the studies [35] and low for the overall evidence (Table 6).
De Lignieres et al. performed a randomized,
placebo-controlled, double-blind, crossover study in 20
women with MM [31]. The diagnosis was not made ac-
cording to ICHD criteria. The authors reported a reduc-
tion in the occurrence and severity of attacks and in the
use of aspirin. Menstrual attacks occurred in 30.8% of
the estradiol cycles and in 96.3% of the placebo cycles
(P < 0.01). Attacks that occurred during estradiol treat-
ment were considerably milder and shorter than those
occurring during placebo treatment and were associated
with less use of aspirin. One out of 20 patients had mi-
graine three days after stopping estradiol treatment.
Dennerstein et al. performed a randomized,
placebo-controlled, double-blind, cross-over study in 22
women with MM [32]. The diagnosis was not made ac-
cording to ICHD criteria. The authors reported no dif-
ference in the occurrence of all attacks, but a reduction
of moderate to severe intensity attacks. Overall there
were no significant differences in the occurrence of mi-
graines between pre- and post-treatment cycles. There
was a significant difference in the occurrence of moder-
ate to severe intensity migraine during the months of
treatment with percutaneous estradiol compared with
placebo gel (t = 2.67; P < 0.05). As the authors considered
that treatment would not be expected to affect migraine
which occurred prior to or after the use of the gel, they
performed a further analysis with these migraines omit-
ted. They found that the alleviation of headaches by per-
cutaneous estradiol compared with placebo was then
significant (t = 3.96; P < 0.001). Additionally, significantly
less medication was utilized during percutaneous estra-
diol use, compared with placebo.
MacGregor et al. performed a randomized,
double-blind, placebo-controlled, crossover study in 37
women with PMM or MRM [35]. The diagnosis was
made according to ICHD-2 criteria. The authors re-
ported a reduction in migraine days and attack severity.
Estradiol was associated with a 22% reduction in mi-
graine days per woman (relative risk [RR] 0.78; 95% CI
0.62 to 0.99). These attacks were also less severe (P =
0.03) and there was evidence that they were associated
with less nausea, although this difference was not signifi-
cant. However, in this study authors found an increase
in migraine occurrence in the 5 days immediately fol-
lowing estradiol use compared to placebo (RR 1.40; 95%
CI 1.03 to 1.92, P = 0.03). Of the 22 women who bene-
fited from using the estradiol gel (they had fewer mi-
graines compared to using placebo), 15 experienced
post-gel migraine (they had more migraine days during
the 5 days after the estradiol gel compared to the 5 days
after placebo). In this study a fertility monitor was used
to predict menstruation and hence to indicate when to
apply the gel.
In the available studies, no serious adverse events were
reported associated with the use of estradiol gel. Some
of the patients experienced cutaneous rash, anxiety, or
amenorrhea. Estradiol use was also associated with an
increase in the length of the follicular phase [35].
In conclusion, current evidence on the use of transder-
mal estradiol supplementation with gel in women with
migraine is limited. Transdermal estradiol supplementa-
tion with gel is easy and well tolerated, thus offering
considerable advantages over other strategies of estrogen
administration. One challenge is to predict when to
apply the gel especially in women with irregular men-
struation. Fertility monitors may be useful but are not
always practical in daily life. Possible benefits may be
offset by an increase in migraine following gel use, asso-
ciated with an iatrogenic delayed estrogen withdrawal.
Possible reasons for the occurrence of post-gel estrogen
withdrawal migraine are that the dose of estradiol was
inadequate; the duration of treatment was too short; or
perhaps that exogenous estrogen inhibits the follicular
rise of endogenous estrogen. Extending the duration of
use of estradiol supplements until endogenous estrogen
had risen might prevent post-supplement estrogen with-
drawal migraine. However, there is no evidence to sup-
port this strategy so far due to the paucity of data and
the possibility of delayed migraine, estrogen supplemen-
tation cannot represent a first-line therapy in women
with MM. However, this option may be considered when
other strategies have failed or are not feasible. Women
should be aware that delayed migraine may occur and in
those circumstances treatment should be withheld. Rec-
ommendations for the transdermal estradiol supplemen-
tation with gel are reported in Table 5.
Transdermal estradiol supplementation with patch
Four studies assessed the possible benefits of transdermal
estradiol supplementation with patch in women with
PMM [29, 38] or MM [33, 37]. Three studies were inter-
ventional [29, 37, 38] and one was observational [33]. The
study drug was estradiol patch releasing from 25 to 100
μg/24 h. In all the studies treatment was specifically pre-
scribed for headache management. Details of the studies
are reported in Table 3. The quality of evidence was rated
as low for all the available studies (Table 4 and Table 6).
Almen-Christensson et al. performed a randomized,
placebo-controlled, double-blind, crossover study in 38
women with PMM [29]. The diagnosis was made ac-
cording to ICHD-2 criteria. The authors addressed as ac-
tive treatment estradiol 100 μg/24 h transdermal patch.
The treatment was compared with placebo. Women
started treatment 7 days before the estimated onset of
menstrual bleeding and continued for two weeks; this
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was repeated for three consecutive menstrual cycles.
The study was prematurely stopped because of difficul-
ties in recruitment. Authors did not find any benefit in
number, severity, and intensity of migraine attacks.
Guidotti et al. performed an observational, prospect-
ive, parallel group, open-label study in 38 women with
MM [33]. The diagnosis was made according to ICHD-2
criteria. The authors addressed as active treatments es-
tradiol 25 μg transdermal patch or frovatriptan or na-
proxen sodium. Each treatment was started 2 days
before expected onset of menstrual headache and con-
tinued for 6 days for a single cycle. Authors reported
that frovatriptan was associated with reduced migraine
incidence and severity while they did not report benefits
from transdermal estradiol.
Pradalier et al. performed a randomized, open-label
study in 24 women with MM [37]. The diagnosis was
made according to ICHD-1 criteria. The authors stud-
ied two different doses of the estradiol patch (25 vs 100
μg/24 h). There was 1 cycle of observation and 2 cycles
of treatment. The authors found that the high dose was
associated with no attacks or decreased number of at-
tacks in 8/12 patients while the low dose was associated
with no attacks or decreased number of attacks in 2/12
patients. MM occurred in 11/12 patients treated with
the low dose and in 6/12 patients treated with the high
dose. More patients used rescue treatments with the low
dose (10 patients) than with the high dose (4 patients;
P < 0.05).
Smite et al. performed a randomized, placebo-controlled
study in 20 women with PMM [38]. The diagnosis was
made according to ICHD-1 criteria. The authors ad-
dressed as active treatment estradiol 25 μg/24 h transder-
mal patch. The treatment was compared with placebo.
There were 6 days of treatment for each cycle (estradiol-
placebo-estradiol or placebo-estradiol-placebo). The
authors did not find any difference in presence, duration,
and severity of migraine attacks and in the use of analge-
sics between active treatment and placebo.
Adverse events related to transdermal estradiol supple-
mentation occurred in a variable proportion across stud-
ies and were not serious. They consisted of increased
headache, local skin reactions, nausea, early bleeding
and increased blood pressure [29, 33, 37, 38].
In conclusion, current evidence on the use of transder-
mal estradiol supplementation with patch in women
with MM or PMM is limited. As the aim of transdermal
estradiol supplementation is to maintain estradiol
concentrations stable at the time of the anticipated
start of the bleeding and migraine attacks, dosing and
timing of treatment are very important. Authors of
the available studies pointed out that 25 and 50 μg of
estradiol supplementation may be too low to achieve
clinical benefits whereas higher doses may increase
risk of ischemic stroke [33]. Also, duration of estra-
diol supplementation may impact on efficacy. Limita-
tions of transdermal estradiol supplementation may
also include difficulties in establishing the time of
ovulation. As there are currently no data showing
benefits of estradiol supplementation with patches on
migraine occurrence, this cannot be considered as a
possible therapeutic option. Recommendations for the
transdermal estradiol supplementation with patch are
reported in Table 5.
Transdermal estrogen supplementation with patch in
women with induced in pharmacological menopause
One study assessed the possible benefits of transdermal
estrogen supplementation with patch in women with
MO and MA, in whom a pharmacological menopause
was induced [12]. The study had an interventional de-
sign. Treatment was specifically prescribed for headache
management. Details of the study are reported in Table
3. The quality of evidence was rated as high for this
study (Table 6). The overall quality of evidence for the
specific treatment was considered as low, because of evi-
dence was not replicated by other studies.
Martin et al. performed a randomized, placebo con-
trolled, parallel group study in 23 women with MO and
MA [12]. The diagnosis was made according to ICHD-1
criteria. All patients received a 3.6 mg goserelin implant to
induce medical oophorectomy. Thereafter women were
randomized to estradiol 100 μg/24 h every 6 days vs pla-
cebo patches. The study was performed in the setting of
headache and internal medicine clinic. There was a
2-month randomization period. The authors found a 34%
improvement (P = 0.025) in the headache index, a 24% im-
provement (P = 0.003) in headache severity, and a 39% im-
provement (P = 0.035) in disability during treatment as
compared to pre-treatment phase. No improvements were
observed in women allocated to placebo. Adverse events
were reported in 9 women and included urticaria, worsen-
ing depression, and worsening headaches.
In conclusion, evidence referring to the use of transder-
mal estradiol supplementation in women induced in
pharmacological menopause is very limited, but a single
study showed some benefits [12]. This condition is associ-
ated with risk of osteoporosis, depression, irritability, hot
flashes, decreased libido and vaginal dryness which how-
ever could be minimized by estrogen add-back therapy.
Medical menopause associated with estradiol treatment is
not appropriate for most women of reproductive age but
future studies need to address its utility in women who
have worsening of their headache during the perimeno-
pause. Recommendations for the transdermal estradiol
supplementation with patch in women induced in
pharmacological menopause are reported in Table 5.
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Subcutaneous estrogen implant plus cyclical progestogen
One study [36] assessed a subcutaneous estrogen implants
in women with MM. The study had an observational de-
sign. Treatment was specifically prescribed for headache
management. Details of the study are reported in Table 3.
The quality of evidence was rated as low (Table 4).
Magos et al. performed a retrospective, observational,
cross-over study in 24 women with MM with and without
aura [36]. The diagnosis was not made according to ICHD
criteria. Authors addressed as active treatment an estradiol
implant (100 mg then decreased to 50 mg) plus norethis-
terone 5 mg/day for 7 days per month to induce menstru-
ation. The implants were inserted in the subcutaneous fat
of the lower abdominal wall. Patients were included in this
study specifically to treat migraine after failure of previous
treatments. Mean duration of treatment was 2.5 years.
Pre- and post-treatment observation periods were not de-
fined and authors did not provide any information about
migraine frequency, severity or disability before and after
treatment. No use of headache diaries was reported. In
this study, all but one patient noted an improvement in
their menstrual migraine following treatment. Eleven
(46%) became completely headache-free and nine (37.5%)
gained almost complete symptomatic relief. All these pa-
tients were able to reduce or stop previous therapy and
considered the implant treatment to be the most effective.
Three patients (12–5%) reported partial relief, and one pa-
tient (4%) gained no benefit. No adverse events or side ef-
fects were reported.
In conclusion, current evidence on the use of subcuta-
neous estrogen implants in women with MM is very
limited. In women with MM, there are not enough data
to assess if the use of the subcutaneous implants may
improve migraine. The only available study did not
provide information in a sufficient rigorous way to fully
assess benefits and disadvantages of treatment. Due to
the promising benefits reported by the single available
pilot study, further data are needed to evaluate possible
advantages related to treatment. Recommendations for a
subcutaneous estrogen implant plus cyclical progestogen
are reported in Table 5.
Discussion
Our systematic review revealed that available evidence re-
ferring to the use of estrogens and progestogens in women
of reproductive age and their effect on migraine is limited.
All the recommendations were based on low quality evi-
dence. There is no evidence on how to manage women
with headache attributed to the use of estrogens. The
strength of recommendation was rated as low in all cases.
Further, most of the contraceptive hormone strategies
were evaluated in the gynecological setting in women who
required estrogens and/or progestogens for contraception
or medical reasons. Much more limited is the evidence on
the use of those drugs in the headache setting in women
who do not require them for gynecological reasons.
Available data, albeit very weak, indicate that the deso-
gestrel 75 μg /day pill is the option which may offer
more evident benefit on migraine course. From a cardio-
vascular point of view in women with migraine it is also
the safest form [22, 46]. The desogestrel pill may im-
prove migraine frequency and severity in women with
MA or MO not necessarily related to menstruation.
However, it has been addressed only in women who re-
quired it for contraception or medical reasons and no
studies specifically aimed to evaluate this drug as a spe-
cific therapeutic option for women with migraine is
available. It is important to note that in some patient the
desogestrel pill may worsen migraine or may be associ-
ated with new onset migraine. Unfavorable bleeding pat-
terns are a common cause for cessation of treatment [6].
The extended regimen of CHC either oral or with the
patch is a further strategy to consider in women with
migraine. As compared to regimens with hormone-free
intervals, this strategy appears more beneficial. However,
even in this case data are preliminary and evidence is
limited to women who require CHC for contraception
or medical reasons. This option is not suggested for
women with MA or for women with MO and additional
vascular risk factors. Although no studies addressed spe-
cifically the issue, Panelists suggested trying this option
for women with estrogen withdrawal headache, particu-
larly those women already experiencing headache or mi-
graine during the pill-free interval. Less certain is the
option of a shortened pill-free interval. No eligible stud-
ies were found evaluating the effects of the conventional
21/7 oral CHC. This is probably because observational
epidemiological studies indicated that this contraceptive
method is associated with de novo occurrence of mi-
graine or migraine worsening in a substantial proportion
of female migraineurs, although no studies record
whether the attacks occur during pill taking or during
the pill-free interval [47–50]. It is important to note that
migraine may improve in some patients with the use of
oral CHC [51], but unfortunately there are no tools or
clinical features to predict the course of migraine after
oral CHC initiation.
In women who have menstrual attacks of migraine
during natural cycles, a therapeutic option may the ad-
ministration of estradiol gel. However, this option may
be associated with delayed headache and is feasible only
in those who have predictable bleeding and predictable
migraine. Estradiol supplementation with patches is a
further possibility. However, as evidence referring to the
optimal dose of the patch is unclear, it is not suggested.
In conclusion, this statement provides evidence-based
and expert-agreed guidance to clinicians for the manage-
ment of migraine with exogenous estrogens and
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progestogens. The available evidence is weak and further
research in needed to clarify which are the best estrogens
and progestogens options in women with migraine. Further
studies should also establish whether the treatments dis-
cussed may be specifically applied to treat migraine in se-
lected women.
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